Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Mereo BioPharma Group plcNASDAQ: MREO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $6.72M (cash outflow) fell 47.9% year over year, behind the -24.3% change in trailing-twelve-month net income. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Net income amounted to 8375.6% of revenue in FY2025.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$9.86M (-76.5%) for the fiscal year ending Dec 2026, a slowdown from the -3.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.72M-8.6% QoQ
- Last fiscal yearDec 2025
- -$41.88M-3.2% YoY
- LTMMar 2026
- -$35.71M-24.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -47.9% | -91.2% | -43.3 pp |
| 1 year | -3.2% | -76.5% | -73.3 pp |
| 3-year CAGR | -0.3% | -36.8% | -36.5 pp |
| 5-year CAGR | -40.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (41.88M) USD
- Year-over-year change
- +3.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.88M) | +3.2% |
| FY2024 | 2024-12-31 | (43.25M) | -46.8% |
| FY2023 | 2023-12-31 | (29.47M) | +30.2% |
| FY2022 | 2022-12-31 | (42.22M) | -319.7% |
| FY2021 | 2021-12-31 | 19.22M | — |
Net Income vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -24.3% is the 9th highest of 10, against a peer median of +37.5%.
- Net income amounts to 7142.0% of revenue for MREO, versus a peer median of 1593.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.71B USD | +146477.0% | +53.5% | — | |
| LTM Mar 2026 | $156.4M USD | +7.6% | +77.4% | — | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $87.5M USD | -19.9% | +19.0% | — |
| LTM Dec 2025 | CHF 70.34M CHF | +38.1% | -1.7% | 1968.6% | |
| FY2025 | A$61.43M AUD | +43.8% | +24.0% | 1218.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M USD | +17.3% | +35.2% | — |
| LTM Mar 2026 | $54.42M USD | +37.5% | +26.7% | — | |
| LTM Mar 2026 | €45.62M EUR | +51.2% | -14.2% | 339.4% | |
| LTM Mar 2026 | $35.71M USD | -24.3% | -0.3% | 7142.0% | |
| LTM Mar 2026 | $27.37M USD | -52.6% | -18.3% | — | |
| Peer median (excluding MREO) | — | +37.5% | +22.4% | 1593.3% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 19.22M | (42.22M) | (29.47M) | (43.25M) | (41.88M) |
| Depreciation & Amortization | 866.47K | 889K | 1.06M | 1.09M | 622K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.46M | 4.77M | 4.92M | 7.39M | 7.6M |
| Change in Working Capital | (2.49M) | (2.35M) | (1.59M) | (369K) | (3.21M) |
| Accounts Receivables | (794.94K) | (3.47M) | 456K | (1.65M) | 1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 617K | (1.26M) | 146K | (1.38M) |
| Other Working Capital | (1.7M) | 498K | (786K) | 1.13M | (3.23M) |
| Other Non-Cash Items | (29.12M) | (9.91M) | 3.94M | 2.31M | 5.9M |
| Operating Cash Flow | (7.07M) | (48.82M) | (21.13M) | (32.83M) | (30.97M) |
| Capital Expenditures | (722.06K) | (13K) | (419K) | (699K) | (20K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 153.86K | 2M | (419K) | 0 | 0 |
| Investing Cash Flow | (568.2K) | 1.99M | (419K) | (699K) | (20K) |
| Debt Repayment | (933.95K) | 0 | (3.19M) | 0 | 0 |
| Common Stock Issued | 105.99M | 0 | 11.61M | 47M | 327.76K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (253.73K) | 200K | 24K | (853K) | (764) |
| Financing Cash Flow | 104.8M | 200K | 7.97M | 46.15M | 327K |
| Effect of Forex Changes | (1.57M) | (12.58M) | 2.82M | (233K) | 1.93M |
| Net Change in Cash | 95.59M | (59.22M) | (10.76M) | 12.38M | (28.81M) |
| Free Cash Flow | (7.79M) | (48.83M) | (21.55M) | (33.53M) | (30.99M) |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.